| 2020-RAMA-68860 | |
| Purdue University researchers have identified a class of compounds for use in treating gonorrhea infection. Strains of Neisseria gonorrhoeae, the bacterial agent responsible for gonorrhea infections, resistant to most contemporarily used antibiotics are becoming more prevalent. This fact has made gonorrhea a national and international health crisis as health agencies around the world consider gonorrhea a serious threat. To make matters even worse, major pharmaceuticals companies often abandon antibiotics research projects due to non-profitability. Thus new compounds have to be identified to combat this gonorrhea superbug. Researchers at Purdue University identified a class of compounds that kill Neisseria gonorrhoeae cells. The researchers screened the most potent compounds against a panel of Neisseria gonorrhoeae strains. Three compounds exhibited potent activity against the Neisseria gonorrhoeae panel with the most potent having MIC values of 0.25 – 2 micrograms per milliliter. These compounds show promise for treatment of gonorrhea across the world and could help alleviate the growing concern of antimicrobial resistance. Advantages: -Novel neisseria gonnorrhea treatment option Potential Applications: -Antimicrobial resistance -Decreasing spread of STDs |
|
|
|
|
Sep 12, 2023
NATL-Patent
United States
(None)
(None)
Mar 23, 2022
PCT-Patent
WO
(None)
(None)
Mar 23, 2022
NATL-Patent
Republic of Korea
(None)
(None)
Mar 23, 2022
NATL-Patent
Australia
(None)
(None)
Mar 23, 2022
NATL-Patent
China
(None)
(None)
Mar 23, 2022
NATL-Patent
European Patent
(None)
(None)
Mar 23, 2022
NATL-Patent
Japan
(None)
(None)
Mar 23, 2022
NATL-Patent
Canada
(None)
(None)
Mar 26, 2021
Provisional-Patent
United States
(None)
(None)
Apr 9, 2020
Provisional-Patent
United States
(None)
(None)
|
|
|
Purdue Office of Technology Commercialization The Convergence Center 101 Foundry Drive, Suite 2500 West Lafayette, IN 47906 Phone: (765) 588-3475 Fax: (765) 463-3486 Email: otcip@prf.org |
